Every material Form 8-K Whitehawk Therapeutics, Inc. has filed with the SEC since May 21, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Whitehawk Therapeutics reported a third-quarter 2026 net loss of $21.2 million, up from $17.7 million a year earlier, as research and development expenses rose to $18.1 million from $14.3 million. The company reported no revenue in the quarter and said its cash, cash equivalents and short-term investments of $169.7 million should fund operations into the second half of 2028.
Q3 2026 net loss was $21.2 million, compared with $17.7 million in Q3 2025.
Research and development expenses were $18.1 million, compared with $14.3 million a year earlier.
Cash, cash equivalents and short-term investments were $169.7 million as of September 30, 2026, versus $145.7 million at December 31, 2025.
The Phase 1 trial of HWK-206 began in the U.S., and the FDA granted it Fast Track designation; initial Phase 1 data from HWK-007 and HWK-016 are expected in the first half of 2027.
Whitehawk Therapeutics increased its board from nine to ten directors and appointed Vijay Iyengar, M.D., as a Class III director effective September 9, 2026. Dr. Iyengar previously served as Executive Vice President at Incyte Corporation until November 2025, and the filing describes his oncology and life sciences experience as the basis for his appointment.
Board size increased from nine to ten; Dr. Iyengar's term expires at the 2029 annual meeting
Non-employee director base annual retainer of $40,000 under the Outside Director Compensation Policy
Initial stock option grant of 76,080 shares, vesting monthly over three years
Served as Executive Vice President at Incyte Corporation from May 2022 to November 2025
Whitehawk Therapeutics reported a second-quarter 2026 net loss of $16.6 million, down from $52.6 million a year earlier, as research and development spending fell to $12.9 million from $48.8 million. The company said cash, cash equivalents and short-term investments were $190.0 million at June 30, 2026, which it expects to fund operations into 2H 2028.
Net loss per share was $0.20 in Q2 2026 versus $0.76 in Q2 2025.
R&D expenses were $12.9 million versus $48.8 million; the prior-year quarter included a $38.0 million up-front license fee paid to WuXi Biologics.
Cash, cash equivalents and short-term investments totaled $190.0 million at June 30, 2026, including proceeds from an $87.5 million private placement announced in May 2026.
The company reported no revenue in either Q2 2026 or Q2 2025.
Whitehawk Therapeutics entered an option agreement with Hangzhou DAC Biotechnology for access to the CPT113 linker-payload for use in up to five additional antibody drug conjugate (ADC) programs. The filing does not disclose financial terms, and the company said Hangzhou DAC's DXC006, which uses CPT113, will present data at ASCO.
Option agreement gives Whitehawk access to CPT113 for up to five additional ADC programs; the filing gives no financial terms.
Whitehawk expects to submit IND applications for multiple new programs over the next 12-24 months.
Hangzhou DAC's DXC006 data were accepted for oral presentation at ASCO; the company's HWK-007 trial-in-progress poster is scheduled for May 30, 2026.
Phase 1 data for HWK-007 and HWK-016 are expected in the first half of 2027.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Whitehawk Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →